


ResistancePlus[®] GC

N. gonorrhoeae + ciprofloxacin susceptibility

Smarter Diagnostics. Simplified Patient Care.



Up to 70% of gonorrhoea infections could be treated with ciprofloxacin, a simple oral antibiotic.¹⁻⁴

- ▶ Guidelines for gonorrhoea management call to preserve ceftriaxone and recommend use of ciprofloxacin when susceptibility information is available.^{5,6}
- ▶ Azithromycin resistance is rising, compromising dual-therapy options.^{5,7,8}
- ▶ Ciprofloxacin has higher efficacy for pharyngeal infections, a site where ceftriaxone is less effective.^{9,10}

ResistancePlus[®] GC is a multiplex qPCR test for detection of *Neisseria gonorrhoeae* and *gyrA* markers linked to ciprofloxacin susceptibility.¹¹⁻¹³ Dual *N. gonorrhoeae* targets improve clinical specificity, while ciprofloxacin resistance and susceptibility targets are included for additional confidence.

ResistancePlus[®] GC is validated for a range of specimen types¹⁴ and powered by proprietary **PlexPCR**[®] technologies demonstrating improved multiplex performance compared with other probe-based tests.¹⁵

Single-well **PlexPCR**[®] test

Channel	Target
1	<i>N. gonorrhoeae</i> (Opa)
2	<i>N. gonorrhoeae</i> (PorA)
3	<i>gyrA</i> S91 wild type
4	<i>gyrA</i> S91F mutation
5	Internal Control

SpeedX Analysis for **ResistancePlus**[®] GC

Improve laboratory productivity with a validated software solution for automated result calling and simple data processing. Streamlined workflow to support rapid, routine diagnostics — with audit trails and user traceability. Included in kit costs and installed on a high security and GDPR compliant platform, with LIS compatibility.

Demonstrated clinical performance¹⁴

	GC Detection	<i>gyrA</i> Detection
Sensitivity	96.9%	100%
Specificity	99.7%	98.6%

Validated for urine, swabs (anal, rectal, cervical, vaginal, urethral, pharyngeal, eye) and extracts.¹⁴

- ▶ A single test solution to determine infection and inform possible alternative treatment.
- ▶ Ideal for confirming GC positives or upfront testing with simultaneous resistance status.
- ▶ Easily obtain resistance/susceptibility data on difficult to culture specimens.
- ▶ Pack sizes to suit your test requirements with no minimum test volumes.
- ▶ Positive, negative, and amplification control materials available.

ResistancePlus[®] GC Confirm infection and inform treatment

Product	Compatible	Size	Cat#
ResistancePlus [®] GC [*]	LC480 II	100 reactions	2011001
		25 reactions	2011025
	ABI 7500/ 7500 Fast/Dx	100 reactions	2013001
		25 reactions	2013025
ResistancePlus [®] GC Control	All platforms	10 reactions	95003
PlexPCR [®] Amplification Control	All platforms	400 reactions	90002

References: 1. Harris SR et al. Lancet Infect Dis Published online May 15th 2018. 2. Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015 3. Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5 4. Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7):1-19 5. Fifer H, et al. 2018 UK national guideline for the management of infection with *Neisseria gonorrhoeae* (Draft). 6. Bignell C & Unemo M. 2012 European Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults. 7. Wi T et al. PLoS Med 2017;14(7). 8. Bolt H et al. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/567602/GRASP_Report_2016.pdf 9. Lewis DA. Sex Transm Infect 2015;91:234-237. 10. Whittles LK et al. Lancet Infect Dis. 2018 Jul;18(7):716-717. 11. Allan-Blitz LT et al. Sex Transm Dis. 2017 May;44(5):261-265. 12. Trembizki E et al. Lancet Infect Dis. 2016 Sep;16(9):1005-1006. 13. Allan-Blitz LT et al. Clin Infect Dis. 2017 May 1;64(9):1268-1270. 14. **ResistancePlus**[®] GC Instructions for use 15. Tan LY et al. PLOS ONE. 2017; 12(1): e0170087. *Not for sale in USA. **ResistancePlus**[®] GC kits are developed and manufactured by **SpeedX** Pty Ltd, Sydney. **PlexPCR**[®] & **ResistancePlus**[®] are trademarks of **SpeedX** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeedX** Pty Ltd products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

Australia - **SpeedX** Pty. Ltd.

+61 (0)2 9209 4170

sales@speedx.com.au

Suite G16, National Innovation Centre
4 Cornwallis Street, Sydney NSW 2015 Australia

Europe - **SpeedX** Ltd.

+44 (0)333 577 5210

sales.uk@speedx.com.au

Kemp House 152-160 City Road
London EC1V 2NX United Kingdom

Find out more plexpcr.com

